Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Scientific Reports|February 17, 2024
Creating an atlas of normal tissue for pruning WSI patching through anomaly detectionPeyman Nejat, Areej Alsaafin, Ghazal Alabtah, et al.
The American Journal of Surgical Pathology|October 3, 2025
Dual TRBC1-CD3 Immunohistochemistry Shows High Diagnostic Utility in Differentiating Mycosis Fungoides/Sezary Syndrome From Reactive Inflammatory Dermatoses in Skin BiopsiesNatasha E Lewis, David J DiCaudo, Jiehao Zhou, et al.
Digital Health|February 27, 2024
Teledermatology in practice: Report of Mayo Clinic experienceNessa Aghazadeh Mohandesi, Tudor Puiu, Setu Mittal, et al.
Blood Advances|April 7, 2022
Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatmentNicholas Borcherding, Kevin J Severson, Nicholas Henderson, et al.
Dermatology Online Journal|November 10, 2021
Cutaneous B cell pseudolymphoma treated with rituximab and methotrexateJake G Besch-Stokes, Meera H Patel, Caitlin M Brumfiel, et al.
International Journal of Dermatology|December 8, 2022
Characteristics of ulcerated and non-ulcerated necrobiosis lipoidicaAlexander Hines, Richard Butterfield, Blake Boudreaux, et al.
Clinical, Cosmetic and Investigational Dermatology|June 11, 2026
Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled StudyRohit Aggarwal, Elena Peeva, David Franklin Fiorentino, et al.
Journal of the American Academy of Dermatology|June 20, 2018
Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control studyAaron R Mangold, Helen J L Cumsky, Collin M Costello, et al.
Advances in Radiation Oncology|June 7, 2024
Fine-Tuning Low-Dose Total Skin Electron Therapy for Optimal Management of Cutaneous T-Cell Lymphoma: A Comparative Analysis of RegimensBrady S Laughlin, Charles Van Der Walt, Aaron R Mangold, et al.
Advances in Therapy|March 5, 2024
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPTDédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Pageof 9